Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Company to provide a detailed overview of its norovirus clinical program

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Vaxart, Inc. (NASDAQ:VXRT ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Brant Biehn - Senior Vice President, Business Operations Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings.

Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development

Vaxart Provides Business Update and Full Year 2022 Financial Results

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Akebia Therapeutics

Eiger BioPharmaceuticals

Protalix Biotherapeutics

Penny stocks to watch before next year. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 To Watch Before 2023

Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions

Vaxart Names Phillip Lee as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET.

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

Vaxart, Inc. (NASDAQ:VXRT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Sahil Kazmi - B. Riley Securities FBR Operator Greetings, and welcome to the Vaxart's Third Quarter 2022 Business Update and Financial Results Conference Call.

Vaxart, Inc. (VXRT) Q3 2022 Earnings Call Transcript

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022.

VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates

Growing body of clinical evidence supports transformational potential of Vaxart's oral vaccine platform

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Plug Power

Select analysts believe these industry game changers can skyrocket over the next year.

3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall Street

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022.

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

Canopy Growth

Investors looking for bargains should look elsewhere.

2 Struggling Stocks to Avoid Right Now

— Study met primary safety and secondary immunogenicity endpoints —

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022. The Vaxart senior management team will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on the same date to review the data and provide a trial update.

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer

Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board

Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D.

Vaxart, Inc. (NASDAQ:VXRT ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Kumaraguru Raja - Brookline Capital Markets Operator Greetings, and welcome to the Vaxart's Second Quarter 2022 Business Update and Financial Results Conference Call. [Operator Instructions].

Vaxart, Inc. (VXRT) CEO Cezar Floroiu on Q2 2022 Results - Earnings Call Transcript

VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022.

VAXART, INC. (VXRT) Reports Q2 Loss, Lags Revenue Estimates

Top-line data from COVID-19 Phase II study expected in the third quarter of 2022

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

Non-executive director to bring extensive life science industry and finance experience

Vaxart Appoints W. Mark Watson to its Board of Directors

All six proposals approved in the 2022 Proxy Statement

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.

News for Vaxart Stock (VXRT)